The complex pathological cascades leading to both Alzheimer's disease (AD) and Parkinson's disease (PD) involve, at various points, inflammation. Since inflammation is a treatable symptom, understanding how and when it impacts the brain, and where specifically in the brain, would offer important guidance in the development of new treatments, sorely needed in both diseases.
Microglia play an important anti-inflammatory role, and produce a substance, mitochondrial translocator protein (TSPO), whose presence can be used as a marker of regional inflammation. GE180 is a newly developed PET ligand which binds to TSPO and hence can be used in imaging studies to analyze regional inflammation in living patients. In prior studies it has shown regional specificity in multiple sclerosis and brain injury. In the current study, the investigators will be using GE180 to analyze regional and global inflammation in the brains of patients with AD and PD at a single time point.
The results of the current study will provide enriched understanding of inflammation in these conditions, and potentially provide preliminary data to inform design of future interventional trials.

开始日期2018-12-13

申办/合作机构

The Cleveland Clinic Foundation

JPRN-UMIN000030084 / Completed临床1/2期IIT

Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's disease - Practical evaluation of PET studies with three tracers for iPSC derived-neural transplantation

开始日期2017-12-01

申办/合作机构

Kyoto University

100 项与 Flutriciclamide (18F) 相关的临床结果

登录后查看更多信息

100 项与 Flutriciclamide (18F) 相关的转化医学

登录后查看更多信息

100 项与 Flutriciclamide (18F) 相关的专利（医药）

登录后查看更多信息

项与 Flutriciclamide (18F) 相关的文献（医药）

2023-01-01·Frontiers in medicine

A feasibility study for quantitative assessment of cerebrovascular malformations using flutriciclamide ([¹⁸F]GE-180) PET/MRI.

Article

作者: Chen, Yicheng ; Seo, Youngho ; VanBrocklin, Henry F ; Narvid, Jared ; Kim, Sally Ji Who ; Lupo, Janine M ; Pampaloni, Miguel H ; Kim, Helen

Aim:

Neuroinflammation plays a key role in both the pathogenesis and the progression of cerebral cavernous malformations (CCM). Flutriciclamide ([¹⁸F]GE-180) is a translocator protein (TSPO) targeting positron emission tomography (PET) tracer, developed for imaging neuroinflammation. The objectives of this study were to describe characteristics of flutriciclamide uptake in different brain tissue regions in CCM patients compared to controls, and to evaluate flutriciclamide uptake and iron deposition within CCM lesions.

Materials and methods:

Five patients with CCM and six controls underwent a 60 or 90 min continuous PET/MRI scan following 315 ± 68.9 MBq flutriciclamide administration. Standardized uptake value (SUV) and standardized uptake value ratio (SUVr) were obtained using the striatum as a pseudo-reference. Quantitative susceptibility maps (QSM) were used to define the location of the vascular malformation and calculate the amount of iron deposition in each lesion.

Results:

Increased flutriciclamide uptake was observed in all CCM lesions. The temporal pole demonstrated the highest radiotracer uptake; the paracentral lobule, cuneus and hippocampus exhibited moderate uptake; while the striatum had the lowest uptake, with average SUVs of 0.66, 0.55, 0.63, 0.55, and 0.33 for patient with CCM and 0.57, 0.50, 0.48, 0.42, and 0.32 for controls, respectively. Regional SUVr showed similar trends. The average SUV and QSM values in CCM lesions were 0.58 ± 0.23 g/ml and 0.30 ± 0.10 ppm. SUVs and QSM were positively correlated in CCM lesions (r = 0.53, p = 0.03).

Conclusion:

The distribution of flutriciclamide ([¹⁸F]GE-180) in the human brain and CCM lesions demonstrated the potential of this TSPO PET tracer as a marker of neuroinflammation that may be relevant for characterizing CCM disease progression along with QSM.

2017-02-01·Molecular imaging and biology3区 · 医学

Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats

3区 · 医学

Article

作者: Gerhard, Alexander ; Trigg, William ; Hinz, Rainer ; Boutin, Hervé ; Reekie, Tristan ; Lepelletier, Francois-Xavier ; Kassiou, Michael ; Banister, Samuel ; Sridharan, Sujata

PURPOSE:

Over the past 20 years, neuroinflammation (NI) has increasingly been recognised as having an important role in many neurodegenerative diseases, including Alzheimer's disease. As such, being able to image NI non-invasively in patients is critical to monitor pathological processes and potential therapies targeting neuroinflammation. The translocator protein (TSPO) has proven a reliable NI biomarker for positron emission tomography (PET) imaging. However, if TSPO imaging in acute conditions such as stroke provides strong and reliable signals, TSPO imaging in neurodegenerative diseases has proven more challenging. Here, we report results comparing the recently developed TSPO tracers [¹⁸F]GE-180 and [¹⁸F]DPA-714 with (R)-[¹¹C]PK11195 in a rodent model of subtle focal inflammation.

PROCEDURES:

Adult male Wistar rats were stereotactically injected with 1 μg lipopolysaccharide in the right striatum. Three days later, animals underwent a 60-min PET scan with (R)-[¹¹C]PK11195 and [¹⁸F]GE-180 (n = 6) or [¹⁸F]DPA-714 (n = 6). Ten animals were scanned with either [¹⁸F]GE-180 (n = 5) or [¹⁸F]DPA-714 (n = 5) only. Kinetic analysis of PET data was performed using the simplified reference tissue model (SRTM) with a contralateral reference region or a novel data-driven input to estimate binding potential BP_ND. Autoradiography and immunohistochemistry were performed to confirm in vivo results.

RESULTS:

At 40-60 min post-injection, [¹⁸F]GE-180 dual-scanned animals showed a significantly increased core/contralateral uptake ratio vs. the same animals scanned with (R)-[¹¹C]PK11195 (3.41 ± 1.09 vs. 2.43 ± 0.39, p = 0.03); [¹⁸]DPA-714 did not (2.80 ± 0.69 vs. 2.26 ± 0.41). Kinetic modelling with a contralateral reference region identified significantly higher binding potential (BP_ND) in the core of the LPS injection site with [¹⁸F]GE-180 but not with [¹⁸F]DPA-714 vs. (R)-[¹¹C]PK11195. A cerebellar reference region and novel data-driven input to the SRTM were unable to distinguish differences in tracer BP_ND.

CONCLUSIONS:

Second-generation TSPO-PET tracers are able to accurately detect mild-level NI. In this model, [¹⁸F]GE-180 shows a higher core/contralateral ratio and BP_ND when compared to (R)-[¹¹C]PK11195, while [¹⁸F]DPA-714 did not.

2016-11-01·Journal of nuclear medicine : official publication, Society of Nuclear Medicine1区 · 医学

Flutriciclamide (¹⁸F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein

1区 · 医学

Article

作者: Calsolaro, Valeria ; Buckley, Christopher ; Atkinson, Rebecca A ; Hinz, Rainer ; Femminella, Grazia D ; Brooks, David J ; Fan, Zhen ; Edison, Paul ; Waldman, Adam ; Trigg, William

METHODS:

Ten healthy controls, 6 TSPO high-affinity binders, and 4 mixed-affinity binders were recruited. All subjects underwent detailed neuropsychologic tests, MRI, and a 210-min ¹⁸F-GE180 dynamic PET/CT scan using metabolite-corrected arterial plasma input function. We evaluated 5 different kinetic models: irreversible and reversible 2-tissue-compartment models, a reversible 1-tissue model, and 2 models with an extra irreversible vascular compartment. The minimal scan duration was established using 210-min scan data. The feasibility of generating parametric maps was also investigated using graphical analysis.

RESULTS:

¹⁸F-GE180 concentration was higher in plasma than in whole blood during the entire scan duration. The volume of distribution (V_T) was 0.17 in high-affinity binders and 0.12 in mixed-affinity binders using the kinetic model. The model that best represented brain ¹⁸F-GE180 kinetics across regions was the reversible 2-tissue-compartment model (2TCM4k), and 90 min resulted as the optimum scan length required to obtain stable estimates. Logan graphical analysis with arterial input function gave a V_T highly consistent with V_T in the kinetic model, which could be used for voxelwise analysis.

CONCLUSION:

We report for the first time, to our knowledge, the kinetic properties of the novel third-generation TSPO PET ligand ¹⁸F-GE180 in humans: 2TCM4k is the optimal method to quantify the brain uptake, 90 min is the optimal scan length, and the Logan approach could be used to generate parametric maps. Although these control subjects have shown relatively low V_T, the methodology presented here forms the basis for quantification for future PET studies using ¹⁸F-GE180 in different pathologies.

项与 Flutriciclamide (18F) 相关的新闻（医药）

2022-08-01

·GlobeNewswire-Health Care

Ashvattha Therapeutics Announces Preclinical Data at the 2022 Alzheimer’s Association International Conference (AAIC) Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET

Data highlights [18F]OP-801’s differentiated imaging profile as a promising tracer for visualizing the progression of neuroinflammationREDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease. The data were presented by Mackenzie Carlson, a scientific collaborator at Stanford University, in a poster titled, “Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET,” at the 2022 Alzheimer’s Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. “We are encouraged by the data as it supports the potential of our HD-based PET tracer, [18F]OP-801, to be an effective imaging agent for detecting early-stage neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer’s,” said Jeffrey Cleland, Ph.D., Chairman & CEO of Ashvattha Therapeutics. “The data also build on previous studies and validates our hydroxyl dendrimer’s ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells. By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal. These patients will then be treated with the same HD chemically linked to a drug to treat the disease. Ultimately, this means that we will be able to provide physicians insight on how much drug will get to the diseased part of the patient’s brain before the treatment. No other non-invasive approach can achieve this key de-risking of neurological therapy.” Key highlights from the presentation include: At 3.75 months of age, [18F]OP-801 yielded a 3-fold higher PET signal in diseased mice compared to healthy mice demonstrating the superior selectivity of the tracer towards activated macrophages and microglia.No significant differences were observed between healthy and diseased mice in PET images using [18F]GE180.Images from brains of diseased mice at 5 months of age showed significantly greater uptake of [18F]OP-801 when compared to healthy mice in the same age group across the entirety of the brain and especially in regions commonly associated with Alzheimer's disease Chronic activation of macrophages and microglia plays a critical role in the onset and progression of many neurological diseases. While PET imaging has the potential to non-invasively visualize and quantify innate immune responses in vivo, most available PET tracers are not specific for macrophages/microglia. To address this need, Ashvattha is developing a HD-based PET tracer, [18F]OP-801, as a companion biomarker to pair with its HD therapeutics to treat neuroinflammation. About [18F]OP-801 [18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]-OP801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com. Media Contact Jordyn Temperato LifeSci Communicationsjtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2. https://doi-org.libproxy1.nus.edu.sg/10.1002/alz.040661

2022-08-01

·BioSpace

Ashvattha Therapeutics Announces Preclinical Data at the 2022 AAIC Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET

Data highlights [18F]OP-801’s differentiated imaging pro a promising tracer for visualizing the progression of neuroinflammation REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease. The data were presented by Mackenzie Carlson, a scientific collaborator at Stanford University, in a poster titled, “Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PET,” at the 2022 Alzheimer’s Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. “We are encouraged by the data as it supports the potential of our HD-based PET tracer, [18F]OP-801, to be an effective imaging agent for detecting early-stage neuroinflammation, a hallmark of neurodegenerative diseases including Alzheimer’s,” said Jeffrey Cleland, Ph.D., Chairman & CEO of Ashvattha Therapeutics. “The data also build on previous studies and validates our hydroxyl dendrimer’s ability to cross the blood-brain barrier and be selectively taken up by reactive inflammatory cells. By measuring the extent of [18F]OP-801 uptake in the brain, we will be able select patients with HD uptake based on PET signal. These patients will then be treated with the same HD chemically linked to a drug to treat the disease. Ultimately, this means that we will be able to provide physicians insight on how much drug will get to the diseased part of the patient’s brain before the treatment. No other non-invasive approach can achieve this key de-risking of neurological therapy.” Key highlights from the presentation include: At 3.75 months of age, [18F]OP-801 yielded a 3-fold higher PET signal in diseased mice compared to healthy mice demonstrating the superior selectivity of the tracer towards activated macrophages and microglia. No significant differences were observed between healthy and diseased mice in PET images using [18F]GE180. Images from brains of diseased mice at 5 months of age showed significantly greater uptake of [18F]OP-801 when compared to healthy mice in the same age group across the entirety of the brain and especially in regions commonly associated with Alzheimer's disease Chronic activation of macrophages and microglia plays a critical role in the onset and progression of many neurological diseases. While PET imaging has the potential to non-invasively visualize and quantify innate immune responses in vivo, most available PET tracers are not specific for macrophages/microglia. To address this need, Ashvattha is developing a HD-based PET tracer, [18F]OP-801, as a companion biomarker to pair with its HD therapeutics to treat neuroinflammation. About [18F]OP-801 [18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]-OP801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: . Media Contact Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2.

2022-07-18

·GlobeNewswire-Health Care

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 Alzheimer's Association International Conference (AAIC)

– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of [18F]OP-801 in comparison to TSPO-PET for detecting early-stage neuroinflammation – REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced a poster presentation of preclinical data on the sensitivity of its hydroxyl dendrimer-based PET tracer, [18F]OP-801, in comparison to translocator protein 18 kDa [TSPO]-PET, using [18F]GE180 (TSPO-PET), an established PET imaging approach for the detection of neuroinflammation, in a mouse model of Alzheimer’s Disease. The data will be presented by scientific collaborators at Stanford University in a poster at the 2022 Alzheimer's Association International Conference (AAIC) taking place at the San Diego Convention Center in San Diego, CA, and online, July 31 – August 4, 2022. Poster presentation details can be found below: Title: Novel hydroxyl dendrimer-based PET tracer [18F]OP-801 detects early-stage neuroinflammation in 5xFAD mouse model with higher sensitivity than TSPO-PETPoster Number: 60700Poster Session: P1-07 Biomarkers: NeuroimagingPresenter: Mackenzie Carlson, NSF Graduate Research Fellow at Stanford University School of Medicine Date/Time: Sunday, July 31, 2022, 9:15 a.m. – 4:45 p.m. PT Location: San Diego Convention Center Exhibit Hall About [18F]OP-801[18F]OP-801 is a hydroxyl dendrimer-based neuroimaging agent being developed as a companion biomarker and a pharmacodynamic tool for therapeutics to treat neuroinflammation due to neurodegenerative diseases including Alzheimer’s and amyotrophic lateral sclerosis (ALS). This imaging agent was designed to cross the blood-brain barrier — a highly selective membrane that prevents most molecules from reaching the brain and spinal cord — in the presence of inflammation and to enter active microglial cells so they can be seen on images. [18F]OP-801 has been shown to be selectively (>95%) taken up by reactive macrophages/microglia.1 [18F]OP-801 shows promise for visualizing the progression of neuroinflammation with high specificity and sensitivity, warranting clinical investigation. A Phase 1/2 clinical trial of [18F]OP-801 is currently underway in healthy volunteers and ALS patients. About Ashvattha Therapeutics Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from our founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University. HDs chemically conjugated to disease-modifying drugs create novel proprietary HD therapeutics (HDTs) selectively targeting reactive inflammatory cells in disease tissue with localized sustained effects. Ashvattha has initiated multiple programs with HDTs focused on neurology, ocular neovascular disease including neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME), and hyperinflammation in diseases. For more information, visit: www.avttx.com. Media ContactJordyn Temperato LifeSci Communicationsjtemperato@lifescicomms.com 1 Henningfield, C.M., Cleland, J.L., Sharma, R., Green, K.N.Selective targeting of plaque-associated microglia through systemic dendrimer administration in an Alzheimer’s disease model. Alzheimer's & Dementia. 2020; Volume 16. Issue S2. https://doi-org.libproxy1.nus.edu.sg/10.1002/alz.040661

合作

100 项与 Flutriciclamide (18F) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15380

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痴呆	临床2期	意大利	Azienda Ospedaliero-Universitaria di Parma	2016-11-18
复发性多发性硬化	临床1期	加拿大	GE Healthcare Holdings, Inc.	2013-04-01
RRMS	临床1期	加拿大	GE Healthcare, Inc.	2013-04-01
RRMS	临床1期	加拿大	GE Healthcare Holdings, Inc.	2013-04-01
阿尔茨海默症	临床1期	英国	GE Healthcare Ltd. (United Kingdom)	-
诊断试剂	临床1期	-	GE Healthcare, Inc.	-
多发性硬化症	临床1期	加拿大	GE Healthcare Ltd. (United Kingdom)	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03702816 (CTgov)	临床2期	阿尔茨海默症 \| 炎症 \| 帕金森病	24	GE180 PET Scan (Control)	窪壓窪鑰襯蓋窪糧遞願(鹽壓憲築鹹遞遞醖糧鬱) = 艱窪膚艱積夢鬱夢鑰繭積夢鑰醖窪夢糧廠餘鑰 (遞鏇遞簾壓觸範衊壓鹽, 選觸鬱繭壓夢簾醖糧鏇 ~ 繭網獵襯鬱觸築願築壓) 更多	-	2023-05-24
NCT03702816 (CTgov)	临床2期	阿尔茨海默症 \| 炎症 \| 帕金森病	24	GE180 PET Scan (Mild Cognitive Impairment)	窪壓窪鑰襯蓋窪糧遞願(鹽壓憲築鹹遞遞醖糧鬱) = 積鑰選齋網範艱膚網齋積夢鑰醖窪夢糧廠餘鑰 (遞鏇遞簾壓觸範衊壓鹽, 遞獵築鹽鹹糧製壓築夢 ~ 顧觸窪襯鑰願遞餘顧糧) 更多	-	2023-05-24
CNS2018	N/A	-	7	18F ‐ GE180	夢襯繭獵膚夢築窪壓鑰(窪範構鹽範鹽鹽顧壓廠) = 構淵鹹衊鹹顧積選願鏇餘憲膚襯構餘積繭範積 (網獵醖構淵醖鏇積製窪 )	-	2018-10-05